Quarter Comparison
Revenue
Operating Income
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 mgtx-20260813xex99d1.htm EX-99.1 Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatmen
EX-99.1 2 mgtx-20260813xex99d1.htm EX-99.1 Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia - Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million - Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition - Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital to support development and commercialization of AAV2-hAQP1 and bota-vec - Anticipate submission of global regu...
Source
Exhibit EX-99.1
0001104659-26-095491
Filed August 13, 2026 at 12:05 PM UTC. The figures above are from the audited statements, not from this release.